معرفی
Thomas Helleday is a Professor of Chemical Biology at the Karolinska Institutet, affiliated with the Department of Oncology-Pathology and SciLifeLab. His research focuses on exploiting DNA damage response (DDR) and metabolic vulnerabilities in cancer cells.
- Education: Biologist, Professor at 34
- Prior Affiliations: Stockholm University, University of Sheffield, University of Oxford
Key research areas include catalytic medicine (e.g., amplizymes activating DNA repair proteins), synthetic lethality (PARP inhibitors for BRCA-mutant cancers), and metabolic reprogramming in tumors. His work has led to the development of karonudib (MTH1 inhibitor) and TH1579 (mitotic DDR inhibitor), with clinical trials ongoing.
Recent publications highlight advancements in OGG1 inhibition for inflammation, MTHFD2 targeting in AML, and NUDIX hydrolase family exploration. His interdisciplinary lab integrates molecular biology, medicinal chemistry, and clinical translation.
- Scientific Awards: Wallenberg Scholar
- Key Collaborations: University of Sheffield, Novo Nordisk Foundation, European Research Council
Students include Saeed Eshtad (2012 thesis) and Johan Boström (2014 thesis). Funding sources span Swedish Research Council, ERC, Swedish Cancer Society, and industry partnerships.
